Kamen, Charles Stewart
- Roswell Park Comprehensive Cancer Center (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #1,533
- R01 Holder
- Top 10% Funded
- Early Career
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2021 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$3.3M
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#1,533
By linked amount among FY2023 PIs
Earliest Year Loaded
2021
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Kamen, Charles Stewart as a PI. Multi-PI records show the full award amount for context.
- 4UH3CA260602-03UH3Contact PIDisparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting$2.5Maward amount
- 1R01CA281862-01R01Contact PIA Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors$815.9Kaward amount
Award organization
Organizations that administered FY2023 awards listing Kamen, Charles Stewart as a PI.
FY2023 award administered by Roswell Park Comprehensive Cancer Center (NY).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2021First NIH AwardRoswell Park Comprehensive Cancer Center
- 2021$500K Cumulative Funding
- 2021$1M Cumulative Funding
- 2021Entered Top 50% NationallyRanked #8625
- 2022$2M Cumulative Funding
- 2022R01 Grant Holder
- 2023$5M Cumulative Funding
- 2023Entered Top 25% NationallyRanked #1533
- 2023Entered Top 10% NationallyRanked #1533